Author Interviews, Cancer Research, NEJM, NIH, OBGYNE / 05.12.2024
NEJM: Prenatal cell-free DNA Can Detect Occult Maternal Cancer
MedicalResearch.com Interview with:
[caption id="attachment_65321" align="alignleft" width="92"]
Dr. Bianchi[/caption]
Diana W. Bianchi, M.D.
Senior Investigator
Center for Precision Health Research
Director,
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institutes of Health
MedicalResearch.com: What is the background for this study?
Response: The ability of prenatal cell-free DNA (cfDNA) sequencing to incidentally detect maternal cancers has been demonstrated by several retrospective studies from commercial or national laboratories. However, there are no standardized approaches to the identification and medical management of prenatal screening results that might indicate a maternal cancer. We sought to prospectively identify DNA sequencing patterns and other biomarkers that could distinguish which women with nonreportable or unusual cfDNA sequencing results had cancer and to determine the best approach for diagnostic work-up of pregnant people who receive these results.
Dr. Bianchi[/caption]
Diana W. Bianchi, M.D.
Senior Investigator
Center for Precision Health Research
Director,
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institutes of Health
MedicalResearch.com: What is the background for this study?
Response: The ability of prenatal cell-free DNA (cfDNA) sequencing to incidentally detect maternal cancers has been demonstrated by several retrospective studies from commercial or national laboratories. However, there are no standardized approaches to the identification and medical management of prenatal screening results that might indicate a maternal cancer. We sought to prospectively identify DNA sequencing patterns and other biomarkers that could distinguish which women with nonreportable or unusual cfDNA sequencing results had cancer and to determine the best approach for diagnostic work-up of pregnant people who receive these results.
The biopharmaceutical industry has undergone significant transformations in recent years, particularly with the adoption of Quality by Design (QbD) principles. This innovative approach is reshaping the landscape of biopharmaceutical manufacturing by fostering a culture of quality that prioritises proactive measures over reactive solutions. This transformation not only enhances the efficiency of manufacturing processes but also ensures that patients receive safe and effective medications.
John W. Ayers, PhD, MA
Altman Clinical Translational Research Institute
University of California
San Diego, La Jolla
MedicalResearch.com: What is the background for this study?
Response: Crisis pregnancy centers (CPCs) are frequently at the center of news
and policy debates, yet little data exists about where they operate or
what they actually do. To address this gap, we developed
